Targeting glutamine metabolism in MM-sensitized MM cells and primary relapsed/refractory patient samples to venetoclax by inducing metabolic shift and increasing expression and binding of BIM to BCL-2 87. The gene discussed is BCL2L11; the disease is Miyoshi myopathy.